Jyotsna Maddury

Nizam’s institute of medical sciences, India

Title: Cardiovascular Manifestations in Covid-19 Patients

---

Biography

.

Abstract

Most important medical challenge during past two years is the COVID 19  pandemic due SARS-CoV-2 virus.  COVID 19 morbidity is increased in the presence of CAD risk factors. Effect of CAD risk factors and COVID 19 infection are bidirectional. Pre-existing conditions, like cardiovascular disease (CVD), hypertension, diabetes, and obesity, are increases the severity as well mortality  rate of COVID. COVID 19 disease induces multiple cardiovascular manifestations, such as myocarditis, acute myocardial injury, acute myocardial infarction (MI), stress-induced cardiomyopathy, cardiogenic shock, arrhythmias and, subsequently, heart failure (HF) and cardiac arrest. Increase of Troponin suggests a hyper inflammatory state or may be due to acute myocarditis. Elevated troponin without other laboratory markers elevation suggests aggressive COVID-19 disease than myocardial injury. Stress, or takotsubo cardiomyopathy occurred primarily in women with covid 19 and these women have more severe heart failure. The patients with COVID-19 positive, more frequently have  multi-vessel thrombosis, stent thrombosis, and a higher thrombus when compared to COVID-19-negative STEMIs. Because of higher thrombus burden more usage  of GP IIb/IIIa inhibitors and thrombus aspiration and higher heparin doses  to achieve therapeutic activated clotting times were also noted. Patients with pulmonary embolism had significantly higher hs- cTnT and NT pro-BNP levels than those without pulmonary embolism. In COVID-19, arrhythmias noticed are atrioventricular/ventricular block, sinus tachycardia, sinus bradycardia, atrial arrhythmias and ventricular arrhythmias. Consideration for potential drug interactions should be take while treating cardiovascular disease patients with covid 19.